Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening

Rosalind Raine 1, Stephen W Duffy 2, Jane Wardle 3, Francesca Solmi 1, Stephen Morris *, 1, Rosemary Howe 4, Ines Kralj-Hans 5, Julia Snowball 6, Nicholas Counsell 7, Sue Moss 2, Allan Hackshaw 7, Christian von Wagner 3, Gemma Vart 3, Lesley M McGregor 3, Samuel G Smith 2, 3, Stephen Halloran 6, 8, Graham Handley 9, Richard F Logan 10, Sandra Rainbow 11, Steve Smith 12, Mary C Thomas 1 and Wendy Atkin 4

1Department of Applied Health Research, University College London, London WC1E 6BT, UK; 2Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ, UK; 3Department of Epidemiology and Public Health, University College London, London WC1E 6BT, UK; 4Department of Surgery and Cancer, Imperial College London, London W2 1PG, UK; 5Department of Biostatistics, King’s Clinical Trials Unit, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 8AF, UK; 6NHS Bowel Cancer Screening Programme Southern Hub, Royal Surrey County Hospital NHS Foundation Trust, Guildford GU2 7YS, UK; 7Cancer Research UK and University College London Cancer Trials Centre, London WC1E 6BT, UK; 8Department of Biochemistry and Physiology, University of Surrey, Guildford GU2 7XH, UK; 9NHS Bowel Cancer Screening Programme North East Hub, Gateshead Health NHS Foundation Trust, Queen Elizabeth Hospital, Gateshead NE9 6SX, UK; 10NHS Bowel Cancer Screening Programme Eastern Hub, Nottingham University Hospitals, Nottingham NG7 2UH, UK; 11NHS Bowel Cancer Screening Programme London Hub, Northwick Park and St Mark’s Hospitals NHS Trust, Middlesex HA1 3UJ, UK and 12NHS Bowel Cancer Screening Programme Midlands and North West Hub, University Hospitals Coventry and Warwickshire NHS Trust, Hospital of St Cross, Rugby CV22 5PX, UK

Background: There is a socioeconomic gradient in the uptake of screening in the English NHS Bowel Cancer Screening Programme (BCSP), potentially leading to inequalities in outcomes. We tested whether endorsement of bowel cancer screening by an individual’s general practice (GP endorsement; GPE) reduced this gradient.

Methods: A cluster-randomised controlled trial. Over 20 days, individuals eligible for screening in England from 6480 participating general practices were randomly allocated to receive a GP-endorsed or the standard invitation letter. The primary outcome was the proportion of people adequately screened and its variation by quintile of Index of Multiple Deprivation.

Results: We enrolled 265,434 individuals. Uptake was 58.2% in the intervention arm and 57.5% in the control arm. After adjusting for age, sex, hub and screening episode, GPE increased the overall odds of uptake (OR = 1.07, 95% CI 1.04–1.10), but did not affect its socioeconomic gradient. We estimated that implementing GPE could result in up to 165 more people with high or intermediate risk colorectal adenomas and 61 cancers detected, and a small one-off cost to modify the standard invitation (£78 000).

Conclusions: Although GPE did not improve its socioeconomic gradient, it offers a low-cost approach to enhancing overall screening uptake within the NHS BCSP.

*Correspondence: Professor S Morris; E-mail: steve.morris@ucl.ac.uk.
Received 24 July 2015; revised 20 October 2015; accepted 24 October 2015; published online 7 January 2016
© 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
Colorectal cancer (CRC) is the fourth most common cause of cancer death worldwide (Ferlay et al., 2013). In the UK it is the third most common cancer and has the second highest mortality rate (CRUK, 2014). Biennial screening using the guaiac faecal occult blood test (gFOBT) can reduce bowel cancer mortality by up to 25% among people undertaking screening (Hewitson et al., 2008; Scholefield et al., 2012). The National Health Service (NHS) Bowel Cancer Screening Programme (BCSP) introduced biennial screening in England in 2006 and now offers it to all individuals aged 60–74 years.

Screening uptake in England is 56%, varying from 61% in the least deprived to 35% in the most-deprived areas of the country (von Wagner et al., 2011).

The BCSP is delivered by five regional hubs and currently operates independently from general practices. General practitioners (GPs) are notified about their patients’ screening results or if their patients did not have screening, but there is no organised GP involvement. However, data from the BCSP pilot (2000–2002) indicated that lack of GP involvement could be a significant barrier to uptake (Weller et al., 2009), confirming findings from previous studies that endorsement of the programme by a GP practice, or a named GP, may circumvent lack of recognition of the BCSP and enhance screening uptake (Cole et al., 2002; Zajac et al., 2010; Hewitson et al., 2011). No evidence exists on whether GPE can influence the differential uptake in CRC screening between socioeconomic groups. Although the inclusion of the GP’s signature on the screening invitation increases gFOBT uptake, this is costly and time-consuming (Cole et al., 2002; Hewitson et al., 2011). Studies have also shown that naming the relevant general practice is almost as effective at increasing uptake as including the GP’s signature (Hewitson et al., 2011).

We developed four interventions to increase uptake amongst individuals with lower socioeconomic circumstances (SEC), without compromising uptake in any socioeconomic group (Wardle et al., 2015). This paper reports the findings of a cluster-randomised controlled trial (RCT) of one of these interventions: general practitioner (GP) GP practice endorsement (GPE) of the BCSP’s screening invitation, which could potentially be a simple and cheap intervention to embed in the routine BCSP invitation letter. One of the other three interventions that were developed, an enhanced reminder letter targeted at individuals who had not responded to the initial screening invitation, was evaluated at the same time as GPE using a pseudo-factorial design. Patients were only eligible for inclusion in the enhanced reminder study if they did not respond to the initial screening invitation, and those who were eligible were randomly assigned to receive the enhanced reminder or not. Hence the enhanced reminder study is unlikely to affect the evaluation of GPE.

In summary, the aims of this study were to evaluate the impact of GPE on the socioeconomic gradient in CRC screening uptake, and its cost. We also evaluated the impact of GPE on CRC screening uptake overall.

**MATERIALS AND METHODS**

**Intervention.** We convened 18 focus groups in London and Yorkshire to explore reasons for non-uptake of bowel cancer screening amongst 128 individuals, sampled to encompass socially advantaged and disadvantaged groups (Palmer et al., 2014). They reported that lack of GP involvement attenuated the perceived relevance of the BCSP and that GP support for the BCSP carried considerable power. ‘If the letter had come from my GP...I would have taken it more seriously.’ (FG18P6) (Palmer et al., 2014).

We established a Primary Care Advisory Group to develop GPE text that could be easily incorporated into the standard BCSP invitation. The resulting GPE statement appeared as a banner across the invitation letter, linking it to each individual’s registered practice, i.e., ‘Your GP Practice [GP practice name] supports the Bowel Cancer Screening Programme’ (Supplementary Appendix A).

We sought consent from all General Practices in England (N=8142) to add their practice name to the standard BCSP invitation. Letters to practices emphasised that endorsing the BCSP would involve little or no extra work for the practice and were sent on BCSP Hub headed paper, signed by Hub Directors. We sent up to three reminder letters to practices at approximately monthly intervals. The final reminder included an additional message for practices in deprived areas, stating we were ‘particularly keen to include practices that look after patients from more deprived areas because those people are less likely to take part in screening’. In total, 80% of practices (N=6480) granted permission to be part of the study.

**Randomisation and masking.** Randomisation was undertaken through the Bowel Cancer Screening System (BCSS), which identifies the population eligible for screening in each hub. The BCSS was modified to enable selection of invitees belonging to general practices, which had agreed to endorse the BCSP before creation of each invitation letter. Individual randomisation was not feasible for logistical reasons: invitation letters are produced in batches so it was not possible to vary them by individual screening invitee, but it was possible to vary them by day. Therefore, cluster randomisation was used based on day of invitation, with ‘day-within-hub’ constituting the randomisation unit (hub-day). Randomisation ran over 20 consecutive days in June 2013, resulting in 10 clusters of invitees receiving an endorsed invitation letter and 10 control clusters in each of the five hubs (100 clusters in total). Two weeks before the start of each intervention, a random number sequence was generated with a continuous random number for each hub-day. Hub-days above the median random number were allocated to intervention; hub-days below to control. This enabled the BCSS to take account of the dates when GPE invitations needed to be produced by any of the five hubs.

Hubs were not aware of the randomisation schedule and confirmed whether the intervention was included on the standard BCSP invitation letter every day, which the Trial Office checked against the randomisation schedule. Although blinding of hubs was not possible, there was no direct contact with participants. Participants were unaware of the comparator unless a household member received an invitation during the study period that contained different information materials or if they had been invited on a previous occasion and recalled the content of that invitation.

**Inclusion/exclusion criteria.** Individuals were eligible for inclusion in the GPE trial if registered with practices that had previously agreed to endorse the BCSP. If the practice consent was not obtained, individuals from that practice were excluded from the trial.

**Outcome measures and costs.** Participants were considered to have been adequately screened if they had returned a gFOBT kit within 18 weeks of being sent an invitation, which led to a definitive ‘normal’ (no further investigation required) or ‘abnormal’ (requiring referral for further investigation, usually colonoscopy) test result. The 18-week time limit coincided with the date on which the BCSS closes a screening episode to a non-responder. Socioeconomic status was measured using the English Index of Multiple Deprivation (IMD) 2010 (Indices of deprivation 2010, 2011), which comprises 38 indicators, combined into seven domains (Income, Employment, Health and Disability, Education Skills and Training, Barriers to Housing and Other Services, Crime and Living Environment). This provides an overall measure of deprivation experienced by people living in a small area (Lower layer Super Output Area, LSOA). Each LSOA covers ~1500 individuals. Each individual’s postcode was linked to the relevant LSOA. Age and sex were obtained from the BCSP database, which also contained information on the type of screening episode.
whether individuals were being invited for the first time (first-time invitee), being sent a biennial invitation having previously not responded (previous non-responder), or being sent a biennial invitation having been screened before (previous responder). We used the results to estimate the impact of GPE on the detection of colorectal adenomas and cancer in the BCSP.

We calculated the costs of modifying the BCSP IT system to incorporate the GPE as part of the standard invitation. This was based on the actual cost charged to the study to modify the invitation letter. We divided this figure by the number of participants in the intervention arm of the trial to calculate the cost per participant. No additional intervention costs were incurred.

Statistical considerations. The sample size was based on increasing uptake by five percentage points in the lowest IMD quintile (most deprived group) falling to one percentage point increase in the highest quintile; giving an overall 5.4-3.2-1 percentage point difference by quintile. This estimate was based on outcomes considered feasible in research to increase screening uptake (Halloran et al, 2010). Sample size was calculated for each hub separately, assuming a similar proportional effect in each hub. For 90% power to detect a statistical significant change as described above, the estimated numbers required per group (intervention and control) overall were 13,500, 12,200, 11,700, 5,400 and 4,500, assuming that all participants had the composition of Midlands and North West, London, North East, Eastern and Southern Hubs, respectively. We used the maximum of the calculated sample sizes (Midlands and North West Hub). Three further adjustments ensured high statistical power. First, on average each hub sends ~3,000 letters per day. The number of invitations per day varies, so we applied an inflation factor of 1.7 to account for this. Second, we initially predicted that 30% of practices would agree to endorse the BCSP so we increased our sample size by a factor of 100/30, which meant running the trial for 15 days to reach our target sample size of 76,500. Third, we actually conducted the trial for 20 days.

We ran several logistic regression models, based on participant level data with a binary outcome variable indicating whether or not the participant was adequately screened (1 = yes, 0 = no). We ran a univariable model on all participants regressing the outcome against treatment group (1 = GPE intervention, 0 = control) (model 1). Model (2) was a multivariable model on all participants, adjusting for sex, age, hub and screening episode. Models 1 and 2 were then performed stratifying participants by IMD quintile. Model 1 was also performed stratifying participants by sex, age, hub and screening episode, including an interaction term between treatment group and IMD score (as a continuous variable). We investigated whether GPE changed the socioeconomic gradient in uptake (both univariable and multivariable models) by testing for significant differences in the odds ratios (OR) for the treatment group variable in each IMD quintile using Wald tests. Conservative variance estimation was used to allow for correlation of individuals within randomisation clusters but not between clusters, and we used the Huber–White information sandwich method for variance estimation (Huber, 1967; White, 1980).

We calculated average marginal effects and used these to predict the impact of GPE on the detection of colorectal adenomas and cancer in the BCSP.

Analyses were performed on an intention-to-treat basis using SAS v9.3 (SAS Institute Inc., 2011) and Stata v12.1 (StataCorp, 2011).

Study approvals. Individual consent was not required because the intervention took place as part of usual communication from the BCSP. The activities of BCSP are covered by National Information Governance Board approval with regard to the handling of patient-identifiable data (Ref: PIAG 1-08(a)/2003). Ethical approval was obtained from the UK National Research Ethics Service, London-Harrow Ethics Committee, Reference number 12/LO/1396. This study is registered at the ISRCTN (registration number: 74121020).

Role of the funding source. This is a summary of independent research funded by the National Institute for Health Research (NIHR)’s Programme Grants for Applied Research Programme (RP-PG-0609–10106). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

RESULTS

The trial included 265,434 individuals from 98 instead of 100 planned clusters (a protocol violation occurred in two clusters, whereby incorrect randomisation was applied twice). Baseline characteristics were well balanced between the two trial groups and representative of the BCSP population (Table 1) (Logan et al, 2012). Bowel cancer screening uptake was 58.2% and 57.5% in the GPE intervention and control groups, respectively (Table 2). This increase of 0.7 percentage points (7 per 1000 screened individuals) was statistically significant (P < 0.001).

As expected, the absolute proportion of individuals participating in screening decreased with increasing deprivation level: 65.2% of individuals (average across both groups) in IMD quintile 1 (least deprived) participated in screening, compared with 43.3% in IMD quintile 5 (most deprived). Uptake was 0.8 percentage points lower in the intervention group in the least deprived quintile and 1.4 percentage points higher in the most deprived quintile (Table 2).

Before adjustment, the GPE intervention had a non-significant effect on the odds of screening uptake among all participants (OR 1.03, 95% confidence interval (CI) 0.95–1.11, P = 0.49; Table 3). Stratification by sub-group suggested there were differences in the odds of screening uptake by screening history: a 9% increase in the odds of uptake among first-time invitees

| Table 1. Baseline sample characteristics |
|----------------------------------------|
| Standard BCSP invitation + GPE N = 131,423 | Standard BCSP invitation N = 134,011 |
| Median (range) | Median (range) |
| Age (years)a | 65 (59–74) | 65 (59–74) |
| IMD deprivation score | 14.7 (0.5–87.8) | 14.6 (0.5–87.8) |
| % (n) | % (n) |
| Sex | | |
| Female | 51.0 (66,986) | 51.2 (68,591) |
| Male | 49.0 (64,437) | 48.8 (65,420) |
| IMD quintile b | | |
| 1 (Least deprived) | 23.1 (30,350) | 23.3 (31,381) |
| 2 | 23.6 (30,952) | 23.4 (31,340) |
| 3 | 21.3 (27,950) | 21.0 (28,181) |
| 4 | 17.1 (22,450) | 17.2 (23,007) |
| 5 (Most deprived) | 14.6 (19,174) | 14.6 (19,540) |
| Mising | 547 | 562 |
| Hub | | |
| BCSC01 | 27.4 (35,993) | 25.8 (34,598) |
| BCSC02 | 24.2 (31,760) | 30.3 (40,550) |
| BCSC03 | 9.0 (11,818) | 9.9 (13,255) |
| BCSC04 | 16.2 (21,272) | 16.0 (21,439) |
| BCSC05 | 23.3 (30,580) | 18.0 (24,169) |
| Screening episode | | |
| Incident | 52.3 (68,695) | 52.3 (70,134) |
| Prevalent first time invitees | 17.0 (22,287) | 17.6 (23,582) |
| Prevalent previous non-responders | 30.8 (40,441) | 30.1 (40,295) |

Abbreviations: BCSP = Bowel Cancer Screening Programme; GPE = GP endorsement; IMD = Index of Multiple Deprivation

Some subjects were invited just before their 60th birthday.

|Quintile based on national distributions using pre-defined national cut-offs.
Interaction between treatment group and IMD score were non-significant for all participants combined and sub-groups of participants stratified by age, sex, hub and screening episode (Table 3).

After adjusting for age, sex, hub and screening episode, the odds of screening uptake were significantly higher in the intervention group than the control group (OR: 1.06, 95% CI 1.04–1.10, P = 0.001; Table 4), i.e., a 7% increase in the odds of screening. A similar increase was seen within each IMD quintile. However, the adjusted ORs in each IMD quintile were not significantly different from one another (P = 0.045) Table 4).

A 7% increase in the odds of screening (all participants) in the multivariable model, was associated with predictive margins (adjusted average probabilities of uptake) of 0.584 (95% CI 0.581–0.586) in the intervention group and 0.574 (95% CI 0.571–0.577) in the control group. This translates into a 1.7% relative increase in the probability of screening among all participants (0.584/0.574) and a one percentage point absolute increase (0.584–0.574; the average marginal effect). Although this appears to be a relatively small effect, in absolute terms the impact would be large if it was rolled out nationally given the population size. In the 2013/14 fiscal year, the number invited for screening in the BCSP in England was 3 976 616 (BCSSN, 2015). An average marginal effect of one percentage point (0.010) suggests that if GPE were implemented nationally, then 39 766 extra people each year would be screened. In 2013/14, the positivity rate among the screened population was 1.84% (BCSSN, 2015). Evidence suggests that 83% of people with a positive test result attend a specialist screening practitioner clinic and undergo further investigation (Logan et al, 2012), and among those who go on to have further investigations, 10.1% will have a colorectal cancer and 27.2% will have colorectal adenomatous polyps classed as medium or high risk requiring further investigation (Logan et al, 2012). Hence, if GPE

### Table 2. Proportion of people who were adequately screened by age, sex, IMD quintile, hub and screening episode

| Age (years) | IMD quintile | Hub | Screening episode | Standard BCSP invitation + GPE | Standard BCSP invitation |
|-------------|--------------|-----|-------------------|------------------------------|--------------------------|
|             |              |     |                   | % (n)                        | % (n)                    |
| All participants | 58.2 (76 520) | 57.5 (77 122) |
| 60–64        | 55.9 (33 331) | 54.8 (33 480) |
| 65–69        | 61.0 (27 328) | 60.5 (27 466) |
| 70+          | 58.7 (15 807) | 58.8 (16 176) |
| Sex          |              |     |                   | Male                        | Female                   |
| Female       | 60.7 (40 707) | 60.2 (41 290) |
| Male         | 55.5 (35 813) | 54.8 (35 632) |
| IMD quintile |              |     |                   | Hub                         | Hub                      |
| 1 (Least deprived) | 65.2 (19 792) | 66.0 (20 716) |
| 2             | 63.1 (19 530) | 62.6 (19 604) |
| 3             | 59.3 (16 571) | 58.0 (16 336) |
| 4             | 53.0 (11 902) | 51.5 (11 839) |
| 5 (Most deprived) | 44.0 (8433)  | 42.6 (8324)   |
| Screening episode |             |     |                   | Incident 86.4 (59 380) 85.7 (60 119) |
| Prevalent first time invitees | 51.4 (11 465) | 49.4 (11 646) |
| Prevalent previous non-responders | 14.0 (5675)   | 13.3 (5357)   |

Abbreviations: BCSP = Bowel Cancer Screening Programme; GPE = GP endorsement; IMD = Index of Multiple Deprivation. A total of 1109 (547 Standard BCSP invitation + 562 GPE) invitees had missing socioeconomic circumstances, 95% of these were adequately screened (292 Standard BCSP invitation and 562 Standard BCSP invitation alone: univariate results for all participants vs standard BCSP invitation alone: results for all participants combined and sub-groups of participants stratified by age, sex, hub and screening episode, plus including an interaction term between treatment group and IMD score (included as a continuous variable)

### Table 3. Impact on uptake of GPE + standard BCSP invitation vs standard BCSP invitation alone: results for all participants combined and sub-groups of participants stratified by IMD quintile

| Participants stratified by IMD quintile | Univariate | Multivariate* |
|---------------------------------------|------------|---------------|
|                                       | Odds ratio (95% CI) | P-value | Odds ratio (95% CI) | P-value |
| All participants                     | 1.03 (0.95–1.11) | 0.49 | 1.07 (1.04–1.10) | <0.0001 |
| 1 (Least deprived)                  | 0.97 (0.88–1.05) | 0.43 | 1.04 (0.99–1.08) | 0.08 |
| 2                                     | 1.02 (0.95–1.10) | 0.54 | 1.06 (1.02–1.10) | 0.004 |
| 3                                     | 1.06 (0.98–1.14) | 0.16 | 1.08 (1.03–1.13) | 0.001 |
| 4                                     | 1.06 (0.98–1.16) | 0.15 | 1.09 (1.04–1.15) | 0.001 |
| 5 (Most deprived)                   | 1.06 (0.97–1.15) | 0.19 | 1.07 (1.01–1.13) | 0.02 |

Test for equal ORs in each IMD quintile (P-value): 0.27 for all participants, 0.49 for sub-groups.

### Table 4. Impact on uptake of GPE + standard BCSP invitation versus standard BCSP invitation alone: univariate results for all participants combined and sub-groups of participants stratified by age, sex, hub and screening episode, plus including an interaction term between treatment group and IMD score (included as a continuous variable)

| Participants stratified by sub-group | Odds ratio (95% CI) | P-value | P-value for significant interaction with IMD score |
|-------------------------------------|---------------------|---------|--------------------------------------------------|
| All participants                    | 1.03 (0.95–1.11)    | 0.49    | 0.11                                             |
| **Age (years)**                     |                     |         |                                                  |
| 60–64                               | 1.05 (0.98–1.12)    | 0.2     | 0.06                                             |
| 65–69                               | 1.02 (0.92–1.13)    | 0.66    | 0.55                                             |
| 70+                                 | 0.99 (0.89–1.10)    | 0.9     | 0.32                                             |
| **Sex**                             |                     |         |                                                  |
| Female                              | 1.02 (0.94–1.12)    | 0.58    | 0.22                                             |
| Male                                | 1.03 (0.96–1.12)    | 0.4     | 0.13                                             |
| **Hub**                             |                     |         |                                                  |
| BCSC01                              | 0.99 (0.90–1.10)    | 0.91    | 0.42                                             |
| BCSC02                              | 1.11 (0.99–1.24)    | 0.07    | 0.01                                             |
| BCSC03                              | 1.05 (0.88–1.26)    | 0.56    | 0.95                                             |
| BCSC04                              | 1.04 (0.94–1.14)    | 0.47    | 0.31                                             |
| BCSC05                              | 0.97 (0.84–1.13)    | 0.73    | 0.25                                             |
| **Screening episode**               |                     |         |                                                  |
| Incident                            | 1.06 (1.00–1.13)    | 0.045   | 0.68                                             |
| Prevalent first time invitees       | 1.09 (1.01–1.16)    | 0.02    | 0.44                                             |
| Prevalent previous non-responders   | 1.06 (1.00–1.13)    | 0.055   | 0.22                                             |

Abbreviations: CI = confidence interval; IMD = Index of Multiple Deprivation.
Cluster-randomised trial of GP endorsement of bowel cancer screening...were implemented nationally this could detect up to an additional 165 people (39,766 × 0.0184 × 0.83 × 0.272) with polyps classed as high or intermediate risk, and 61 people (39,766 × 0.0184 × 0.83 × 0.101) with a colorectal cancer each year.

GP endorsement increased overall screening uptake although it did not significantly affect the socioeconomic gradient in bowel cancer screening participation. This illustrates the challenge of shifting the gradient in screening participation within the context of a national screening programme.

Given the exceptionally high level of agreement by general practices to endorse the BCSP, the small one-off cost to modify the standard invitation letter, and the overall increase in uptake, we suggest that the BCSP consider adding GPE to the screening invitation letter.

DISCUSSION

The addition of a simple statement of GP endorsement to the standard BCSP invitation letter increased the odds of participation in the gFOBt screening programme by 7% with only a small up-front cost. This translates into a 1.7% relative increase in the probability of screening and a 1% point absolute increase, and represents an almost cost-free approach to enhancing screening uptake, with no effort required from primary care other than agreement to have the practice name on the letters.

GP did not have a significantly stronger effect in lower vs higher socioeconomic groups. This is the first study highly powered to examine effects on the socioeconomic gradient, and the size of the trial indicates that even if the non-significant differences are real, they are not substantial, at least for the format of GPE used.

The increase in overall uptake was smaller than previous studies (Camilloni et al, 2013), which may be because they used a more intensive intervention, with letters directly from the GP or featuring individual GPs’ signatures. However, in the BCSP all invitation letters come from the hubs and keeping up to date with the names of all GPs at every practice would be costly, time consuming and subject to error, as shown previously (Hewitson et al, 2011). The only practical option was to include a banner noting the individual’s general practice supported the programme. Although this approach may have diluted the impact, this should be balanced against the wide coverage, impact on colorectal adenoma and cancer detection, and negligible cost.

The strengths of our trial were its national coverage, the large sample size yielding substantial statistical power to detect small differences in uptake between sub-groups, and easy incorporation of the intervention into the existing BCSP.

There were several limitations. First, it was not possible to use individual randomisation for logistical reasons so a clustered design was used, which could compromise statistical efficiency and increase the required sample size (Campbell, 2014). This was addressed in our sample size calculation, and our sample size target was surpassed. Second, contamination between study groups, such that individuals in the control group were exposed to the GPE intervention, could have occurred, for example, in the unlikely event that different household members were randomised to different arms of the trial during the 4-week study period. Third, our findings may have been influenced by other factors operating within areas and affecting outcomes. For example, it is possible that local initiatives affected uptake in specific regions. This is unlikely to affect our findings because it is improbable that concurrent interventions would occur on the same alternate days as each intervention. Fourth, as part of the programme, we developed four interventions and another trial evaluating a simple enhanced reminder was conducted at the same time as this trial using a pseudo-factorial design. The enhanced reminders targeted individuals who had not responded to the initial screening invitation; individuals who had not responded to the invitation were randomly assigned to receive an enhanced reminder reiterating the screening message or the usual reminder letter. Some participants in the GPE trial were eligible for inclusion in the enhanced reminder trial, and those who were not eligible had all responded to the first screening invitation. Those who were eligible for inclusion in the enhanced reminder study were randomly allocated to receive the enhanced reminder or not. Hence, this has not been adjusted for in our statistical analysis, though there is a chance of residual confounding.

GP endorsement increased overall screening uptake although it did not significantly affect the socioeconomic gradient in bowel cancer screening participation. This illustrates the challenge of shifting the gradient in screening participation within the context of a national screening programme.

ACKNOWLEDGEMENTS

We dedicate this article in memory of Professor Jane Wardle (1950–2015). We thank the managers of the Bowel Cancer Screening Programme screening hubs and staff at Real Digital International for their oversight and management of the interventions; and also Mr Paul Greliat and Dr Cecily Palmer for their contributions to the trial and project management, respectively. We thank Claire Nickerson from Public Health England for providing the data on national screening uptake and positivity for 2013/14. HSCIC provided guidance on formatting of the GP Endorsement and Enhanced Reminder letters. We also thank the Primary Care Advisory Group comprising five GPs, a Practice Manager, a BCSP Hub Director and two clinical academics for their input on the content of the GPE and strategies to engage GPs to endorse the Programme. We also thank our community partners (AgeUK, Community Health and Learning Foundation, Beating Bowel Cancer, Social Action for Health) and our patient representatives for their help with developing and pre-testing intervention materials. This is a summary of independent research funded by the National Institute for Health. Research (NIHR)’s Programme Grants for Applied Research Programme (RP-PG-0609–10106). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The guarantor (RR) confirms that she had full access to all the data in the study and had final responsibility for the decision to submit for publication. RR and MT were partly supported by the NIHR Collaboration for Leadership in Applied Health Research and Care North Thames at Barts Health NHS Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

JW and RR were joint principal investigators. They designed the study and wrote the grant application in collaboration with WA, SD, AH, SMorris, CvW and the hub directors (GH, RL, SH, SR, SS). JW, RR, WA, CvW, IKH, SS, LMcG, GV and MT led the development and testing of the intervention. SD generated the randomisation codes. WA oversaw the recruitment of GP practices and had overall
responsibility for delivery of the intervention. The hubs were responsible for identifying individuals and delivering the intervention assisted by IKH and RH. JS and IKH led the data extraction. SMoss, SD, AH and NC analysed the primary and secondary outcomes. FS, MT and SMorris analysed the cost data. SMorris, FS, RR and MT drafted the paper and all authors contributed to the reviews and revisions. All authors have seen and approved the final version. RR is guarantor.

REFERENCES

BCSSN (2015) National Fiscal Summary 12 June 2015.
Camilloni L, Ferroni E, Cendales BJ, Pezzarossi A, Furnari G, Borgia P, Guasticchi G, Giorgi Rossi P (2013) Methods to increase participation in organised screening programs: a systematic review. BMC Public Health 13: 464.
Campbell MJ (2014) Challenges of cluster randomized trials. J Comp Eff Res 3: 271–281.
Cole SR, Young GP, Byrne D, Guy JR, Morcom J (2002) Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner. J Med Screen 9: 147–152.
CRUK (2014) Cancer Research UK. Available at http://www.cancer researchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence (accessed on 26 June 2015).
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11: Lyon, France. Available at http://globocan.iarc.fr (accessed on 26 June 2015).
Halloran SP, Lawn G, Zappa M (2012) European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition - faecal occult blood testing. Endoscopy 44: SE65–SE87.
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103: 1541–1549.
Hewitson P, Ward AM, Heneghan C, Halloran SP, Mant D (2011) Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial Br J Cancer 105: 475–480.
Huber PJ (1967) The behavior of maximum likelihood estimates under nonstandard conditions. In Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Statistics. The Regents of the University of California.
Indices of deprivation 2010 (2011) Available at http://webarchive.nationalarchives.gov.uk/20120919132719/http://www.communities.gov.uk/

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.